Europe

RCPCH launches a Children’s Health Research Capacity Development Fund

Tuesday, February 9, 2016

Substantial advances have been made over the last decade in preventing and treating disease, but discovery science and biomedical research, essential for the advancement of medicine, remain disproportionately focused upon adult conditions. This has prompted the Royal College of Pediatrics and Child Health (RCPCH) to launch a Children’s Health Research Capacity Development Fund to support a growth in the number of child health researchers in the U.K. and abroad.

[Read More]

EMA sets up task force on Zika virus

Tuesday, February 9, 2016

The EMA has established a task force of European experts with specialized knowledge in vaccines, infectious diseases and other relevant expertise to contribute to the global response to the threat of the Zika virus infection. This group will be available to give advice on any scientific and regulatory matters for the research and development of medicines or vaccines against the virus.

[Read More]

MediSapiens joins international consortium for personalized medicine

Monday, January 25, 2016

MediSapiens, a Finnish developer and provider of Bio-IT solutions for research and biomedicine, is a partner in an international consortium aiming at developing personalized medicine applications using integrated genome and other health data. The consortium was founded and is headed by the Competence Centre on Health Technologies of Estonia (CCHT) in the framework of the Competence Centre program supported via Enterprise Estonia. Along with MediSapiens and CCHT, the other consortium members are the University of Tartu Estonian Genome Center (Estonia), Tallinn University of Technology eMedicine Laboratory (Estonia), BioEximi OÜ (Estonia), Duodecim Medical Publications Ltd. (Finland) and Coimbra Genomics (Portugal).

[Read More]

UCL launches $55M technology investment fund

Wednesday, January 20, 2016

UCL is launching the UCL Technology Fund to invest £50 million ($55 million) in commercializing its research emerging over the next five years. The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof-of-concept, licensing projects and new spinout companies.

[Read More]